** Adds ORCD is set for strong growth over the next three years as new management continues to execute the turnaround strategy well
** Co leveraging core strengths in key active pharma ingredients (APIs)-like anti-microbials such as Cephalosporin,
** Estimates 35%+ compound annual growth rate (CAGR) in earnings before interest, taxes, depreciation and amortisation (EBITDA) over fiscal 2023-2026